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Pncreased Level of Pericardial
nsulin-Like Growth Factor-1 in Patients With
eft Ventricular Dysfunction and Advanced Heart Failure
aoki Abe, MD,* Toshiro Matsunaga, MD,* Kunihiko Kameda, MD,* Hirofumi Tomita, MD,*
akayuki Fujiwara, MD,* Hiroshi Ishizaka, MD,* Hiroyuki Hanada, MD,* Kozo Fukui, MD,†
kuo Fukuda, MD,† Tomohiro Osanai, MD,* Ken Okumura, MD*
irosaki, Japan
OBJECTIVES To test the hypothesis that the cardiac insulin-like growth factor-1 (IGF-1) system is
up-regulated in the failing heart, we measured the pericardial (cardiac) and plasma
(circulating) IGF-1 levels in coronary artery disease patients.
BACKGROUND Local IGF-1 systems are regulated differently from the systemic IGF-1 system. The cardiac
IGF-1 system is up-regulated by the increased left ventricular (LV) wall stress. However, it
remains unknown how this system is affected in LV dysfunction and heart failure.
METHODS We measured the plasma and pericardial fluid levels of IGF-1 and brain natriuretic peptide
(BNP) in 87 coronary artery disease patients undergoing cardiac surgery, and examined their
relationships with LV function and heart failure severity. The expressions of IGF-1 and
IGF-1 receptor proteins were examined in endomyocardial biopsies obtained from other
patients with normal or impaired LV function.
RESULTS The pericardial IGF-1 and BNP levels were positively correlated with the plasma BNP level
(both p 0.001). The pericardial IGF-1 level was increased in heart failure patients, whereas
the plasma IGF-1 level was rather decreased. The pericardial IGF-1 level was inversely
correlated with the LV ejection fraction (p 0.001), whereas the plasma IGF-1 level was not.
Positive immunostaining for IGF-1 and IGF-1 receptor proteins was enhanced in myocardial
biopsies from failing hearts compared with those from nonfailing hearts.
CONCLUSIONS The pericardial IGF-1 level was increased in patients with LV dysfunction and heart failure,
whereas the plasma IGF-1 level was decreased. These results may indicate that up-regulation of
the cardiac IGF-1 system serves as a compensatory mechanism for LV dysfunction. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.06.048Cardiol 2006;48:1387–95) © 2006 by the American College of Cardiology Foundation
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tirculating insulin-like growth factor-1 (IGF-1) is mainly
eleased from the liver in response to growth hormone
ecreted from the pituitary gland, and is chiefly bound to
nsulin-like growth factor binding protein (IGFBP). The
GF-1–IGFBP complex is transported to target organs (or
issues), where the free form of IGF-1 binds to the IGF-1
eceptor and mediates the actions of growth hormone (1).
revious experimental studies have reported several roles for
GF-1 in the heart. Particularly, cardiomyocyte apoptosis
uring reperfusion injury was prevented in IGF-1 trans-
enic mice (2); IGF-1 enhanced ventricular hypertrophy
nd function during the initial phase of experimental cardiac
ailure (3); and IGF-1 showed distinct positive inotropic
roperties by sensitizing myofilaments to Ca2 without
ncreasing myocyte Ca2 currents (4).
On the other hand, local (tissue) IGF-1 systems exist that
re regulated differently from the circulating IGF-1 system
1) and regulate tissue development (1,5–7). Both IGF-1
nd IGF-1 receptor mRNA levels in the myocardium are
p-regulated in an experimental angiotensin II–induced
ypertension model (8). In humans, IGF-1 production in
he heart, which was estimated by the difference in the
From the *Second Department of Internal Medicine and †First Department of
urgery, Hirosaki University School of Medicine, Hirosaki, Japan.c
Manuscript received February 6, 2006; revised manuscript received June 6, 2006,
ccepted June 12, 2006.lasma concentrations between the aorta and coronary
inus, is increased in patients with valvular heart disease (9).
hese experimental and clinical studies suggest that the
ocal cardiac IGF-1 system is up-regulated, presumably by
ncreases in the left ventricular wall stress. However, it
emains unknown how the cardiac IGF-1 system is involved
n the pathophysiology of left ventricular dysfunction and
eart failure induced by coronary artery disease (CAD). In
he present study, we tested the hypothesis that the cardiac
GF-1 system is up-regulated with the progression of left
entricular dysfunction by measuring the pericardial (car-
iac) and plasma (circulating) levels of IGF-1 in CAD
atients, and examining their correlations with parameters
or left ventricular function as well as the pericardial and
lasma levels of brain natriuretic peptide (BNP), a sensitive
iochemical marker for the severity of heart failure (10).
urthermore, we examined the expressions of IGF-1 and
GF-1 receptor proteins in the human endomyocardial
iopsy samples obtained from the patients with or without
eft ventricular dysfunction.
ETHODS
tudy patients. The protocol of the present study was
pproved by the ethics committee of our institution. All of
he patients gave informed consent before the study
ommenced.
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IGF-1 and Heart Failure October 3, 2006:1387–95A total of 87 consecutive patients who underwent elective
oronary artery bypass graft surgery (CABG) for CAD and
iplanar left ventriculography (LVG) before the surgery
ere enrolled between April 2001 and December 2003. The
linical profiles of these patients, including their New York
eart Association (NYHA) functional classes and left
entricular ejection fraction (LVEF), are shown in Table 1.
mong the patients, 5 had single-vessel disease, 17 had
ouble-vessel disease, 65 had triple-vessel disease, and the
emaining 5 had left main trunk disease. The patients were
dministered angiotensin-converting enzyme inhibitor
n  37), angiotensin II type 1 receptor blocker (n  35),
urosemide (n  28), beta-blocker (n  67), aspirin (n 
1), warfarin (n  11), digoxin (n  3), nitrates (n  19),
able 1. Clinical Characteristics of Study Patients
Patients (n  87)
ge (yrs) 66  10
ender (male/female) 54/33
eight (kg) 60  10
eight (cm) 158  1
ody mass index (kg/m2) 24.3  3.0
YHA functional class
I 43
II 31
III 13
aboratory data
Blood sugar (mg/dl) 119  36
Hemoglobin A1c (%) 6.1  1.3
Cholinesterase (IU/I) 121  30
Serum total cholesterol (mg/ml) 191  42
ean resting blood pressure (mm Hg) 128/70
ypertension (%) 68%
iabetes (%) 60%
yslipidemia (%) 47%
moking (%) 55%
VEDVI (ml/m2) 102  29
VESVI (ml/m2) 56  28
VEF (%) 47  14
ubgroups divided by LVEF
30% 18
30% to 50% 38
50% 31
I (l/min/m2) 2.6  0.7
CWP (mm Hg) 11  7
ata are given as mean values  SD.
CI  cardiac index; LVEDVI  left ventricular end-diastolic volume index;
VEF  left ventricular ejection fraction; LVESVI  left ventricular end-systolic
Abbreviations and Acronyms
ANOVA  analysis of variance
BNP  brain natriuretic peptide
CABG  coronary artery bypass graft surgery
CAD  coronary artery disease
IGF-1  insulin-like growth factor-1
IGFBP  insulin-like growth factor binding protein
LVEF  left ventricular ejection fraction
LVG  left ventriculography
NYHA  New York Heart Associationc
olume index; NYHA  New York Heart Association; PCWP  pulmonary
apillary wedge pressure.nd hydroxymethyl glutaryl coenzyme A reductase inhibitor
n  55). Patients with severe renal failure, liver dysfunc-
ion, inflammatory disease, cancer, thyroid disease, or un-
ontrolled diabetes mellitus were excluded. Furthermore,
atients who underwent emergency CABG were excluded.
Before the CABG, cardiac catheterization including cor-
nary angiography and biplanar LVG was performed in all
atients. Two cardiologists who were unaware of the results
or the IGF-1 and BNP levels analyzed the LVG using an
VG analysis system (Cardio 500; Kontron Instruments,
ching, Germany) and determined the left ventricular
nd-diastolic volume index and LVEF.
Ideally, we would have preferred to obtain myocardial
issue biopsy samples during the CABG. However, we were
nable to do it from an ethical point of view. Alternatively,
e examined the expressions of IGF-1 and IGF-1 receptor
roteins immunohistochemically in endomyocardial biopsy
amples obtained from other patients with normal or im-
aired left ventricular function. These patients consisted of
patients with impaired left ventricular function caused by
ilated cardiomyopathy and 4 with ventricular tachycardia
r electrocardiographic abnormalities and with normal
unction. Right ventricular endomyocardial biopsy samples
ere obtained during diagnostic cardiac catheterization. In one
articular patient with left ventricular dysfunction caused by
ilated cardiomyopathy and with massive pericardial effusion,
ho had previously undergone transsphenoidal surgery
gainst acromegaly and had a decreased plasma IGF-1 level
14 ng/ml), pericardial fluid was obtained via a pericardio-
entesis in addition to the endomyocardial biopsy sample.
easurements of the IGF-1 and BNP levels in blood
nd pericardial fluid samples. Pericardial fluid samples
ere obtained during CABG under general anesthesia.
mmediately after the creation of a small incision in the
ericardium, undiluted samples of pericardial fluid were
btained. Samples contaminated with blood were dis-
harged. The samples were collected into sterile tubes,
mmediately placed on ice, clarified by centrifugation at
,000  g for 10 min at 4°C, and rapidly frozen and stored
t 80°C until analysis. The levels of total IGF-1, free
GF-1, and BNP were measured in duplicate using sensitive
nd specific enzyme-linked immunosorbent assays
ELISAs; total IGF-1 by ELISA DSL-10-2800 and free
GF-1 by ELISA DSL-10-9400; Diagnostic System Lab-
ratories, Inc., Webster, Texas), and immunoradiometric
ssays (Shionoria BNP RIA kit, Shionogi, Japan), respec-
ively. The interassay coefficients of variation for total
GF-1, free IGF-1, and BNP were 15%, 6.2%, and
10%, respectively. It is known that IGF-1 is stable in
rozen samples (11). The plasma total IGF-1 and BNP
evels were measured in 39 of the 87 patients. Venous blood
amples (10 ml) were collected in the morning between 6
nd 7 AM while the patients were in a fasting state. After
entrifugation at 3,000  g for 15 min, aliquots were stored
t 80°C until analysis. We also measured the serum
holinesterase level using a spectrometric assay (ChE-CL;
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October 3, 2006:1387–95 IGF-1 and Heart Failureerotec, Sapporo, Japan) as a marker for protein synthesis
ctivity in the liver, and examined its relationships with the
lasma IGF-1 and BNP levels.
mmunohistochemistry for IGF-1 and IGF-1 receptor
roteins. Endomyocardial biopsy samples were fixed in
0% formalin, embedded in paraffin, serially cut into 5-m-
hick sections, and subjected to immunoenzymatic staining
sing the DAKO LSAB system (K0679; DakoCytomation,
arpinteria, California) (12). Briefly, the sections were
re-incubated with 0.3% hydrogen peroxide, washed, and
ncubated with a rabbit polyclonal anti–IGF-1 antibody
5345-0225; Biogenesis, Oxford, United Kingdom; 1:50
ilution) or rabbit polyclonal anti–IGF-1R antibody (sc-
12; Santa Cruz Biotechnology, Santa Cruz, California;
:100 dilution) containing 1% bovine serum albumin for 30
in. After washing, the sections were sequentially incu-
ated with biotinylated anti-rabbit immunoglobulins for 15
in and horseradish peroxidase-conjugated streptavidin for
5 min. Peroxidase activity was visualized with a diamino-
enzidine chromogen solution. Each stained histological
ection was examined under a microscope (Carl Zeiss, Jena,
ermany) connected to a computerized image-analysis
ystem (AxioVision; Carl Zeiss). The degrees of protein
xpression were estimated according to the following scale:
, samples without any staining; 1, samples with weak
taining; 2, samples with moderate staining; 3, samples
ith markedly enhanced staining. This estimation was
igure 1. (A) Relationship between age and the plasma total insulin-like g
otal IGF-1 level. (C) Relationship between the plasma and pericardial brain na
ericardial total IGF-1 levels.erformed by 2 independent investigators without any
nowledge of the patient profiles.
tatistical analysis. All data are shown as mean values  1
D, with the exception of the IGF-1 and BNP levels.
ecause the IGF-1 and BNP levels were not normally
istributed, they are shown as the median with an inter-
uartile range. For comparison of the data between the 2
roups, nonparametric analysis (Mann-Whitney U test) was
sed. For comparison among the 3 groups, analysis of
ariance (ANOVA) with post hoc Bonferroni comparisons
as used. A linear regression analysis was performed to
xamine the correlations between each of the LVG param-
ters and the BNP and IGF-1 levels. We performed a
ultiple regression analysis to examine whether age affects
ssociation of plasma total IGF-1 level with heart failure or
he LVEF. The degrees of immunostaining for IGF-1 and
GF-1 receptor proteins in the biopsy samples were com-
ared between the groups with left ventricular dysfunction
nd normal function using the chi-square test. We used
og-transformed values of BNP (log BNP) for statistical
egression analysis because of the skewed distribution.
alues of p  0.05 were considered significant.
ESULTS
lasma and pericardial levels of BNP and IGF-1. The
ericardial total IGF-1 median level was 27 ng/ml with an
factor-1 (IGF-1) level. (B) Relationship between age and the pericardialrowth
triuretic peptide (BNP) levels. (D) Relationship between the plasma and
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IGF-1 and Heart Failure October 3, 2006:1387–95nterquartile range of 27 ng/ml, and was lower than the
lasma IGF-1 median level of 130 ng/ml with an inter-
uartile range of 88 ng/ml (p  0.0001 by Mann-
hitney U test). The pericardial free IGF-1 median level
as 1.0 ng/ml with an interquartile range of 1.0 ng/ml,
nd was lower than the pericardial total IGF-1 median
evel (p  0.0001 by Mann-Whitney U test). In contrast,
he pericardial BNP median level was 286 pg/ml with an
nterquartile range of 607 pg/ml for all patients, and was
-fold higher than the plasma median level of 153 pg/ml
ith an interquartile range of 285 pg/ml (p  0.0001 by
ann-Whitney U test).
orrelations between age and the plasma and pericardial
evels of IGF-1 and BNP. There was a significant negative
orrelation between age and the plasma total IGF-1 level
Fig. 1A). In contrast, the pericardial total IGF-1 level was
ot correlated with age (Fig. 1B). Neither the plasma nor
he pericardial BNP level was correlated with age (data not
hown). The pericardial BNP level was well correlated with
he plasma BNP level (Fig. 1C). However, the pericardial
otal IGF-1 level was not correlated with the plasma total
GF-1 level (Fig. 1D).
elationships of the IGF-1 and BNP levels with LVEF.
oth the total and free pericardial IGF-1 levels were
egatively correlated with LVEF (total IGF-1: r  0.45,
 0.0001; free IGF-1: r  0.37, p  0.001), whereas the
igure 2. Pericardial total insulin-like growth factor-1 (IGF-1) levels (A), p
atriuretic peptide (BNP) levels (D) in patient groups with left ventricular eject
ompared with the LVEF 50% group.lasma total IGF-1 level was not (r  0.12, p  NS). The
lasma BNP level was negatively correlated with the LVEF
r  0.53, p  0.0001).
Figure 2 shows the pericardial total IGF-1 levels (Fig.
A), free IGF-1 levels (Fig. 2B), plasma total IGF-1 levels
Fig. 2C), and plasma BNP levels (Fig. 2D) in patient
roups with LVEF values of 50%, 30% to 50%, and
30%. The pericardial total and free IGF-1 levels were
ignificantly higher in the LVEF 30% group than in the
VEF50% group (by ANOVA). The plasma total IGF-1
evels did not differ among the 3 groups. The plasma BNP
evel was significantly higher in the LVEF 30% group
han in the LVEF 50% group (by ANOVA).
elationships of the IGF-1 and BNP levels to NYHA
unctional classes. The pericardial total and free IGF-1
evels were significantly higher in the patient group with
YHA functional class III than in the patient group with
YHA functional class I (Figs. 3A and 3B) (by ANOVA).
n the other hand, the plasma total IGF-1 level was
ignificantly lower in the patient group with NYHA func-
ional class III than in the patient group with NYHA
unctional class I (Fig. 3C) (by ANOVA). The plasma BNP
evel was significantly higher in the patient group with
YHA functional class III than in the patient groups with
YHA functional classes I and II (Fig. 3D) (by ANOVA).
fter age was adjusted, the plasma total IGF-1 level was
dial free IGF-1 levels (B), plasma total IGF-1 levels (C), and plasma brainericar
ion fraction (LVEF) values of 50%, 30% to 50%, and 30%. *p  0.01
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October 3, 2006:1387–95 IGF-1 and Heart Failuretill significantly lower in the patient group with NYHA
unctional class III than in the patient group with NYHA
unctional class I (p  0.05).
elationships between IGF-1 and BNP levels. The peri-
ardial total and free IGF-1 levels were both positively
orrelated with the plasma BNP level (Figs. 4A and 4B). In
ontrast, the plasma IGF-1 level was negatively correlated
ith the plasma BNP level (Fig. 4C).
elationships among the plasma total IGF-1 and BNP
evels and the serum cholinesterase level. The serum
holinesterase level (IU/l) was significantly lower in the
atient group with NYHA functional class III (99  19)
han in the patient groups with NYHA functional classes I
128  28) and II (120  33) (both p  0.05). There was
significant positive correlation between the plasma total
GF-1 level and the serum cholinesterase level (r  0.47,
 0.01, n  39) and a significant negative correlation
etween the plasma BNP level and the serum cholinesterase
evel (r  0.37, p  0.01, n  87).
mmunohistochemical analyses of IGF-1 and IGF-1 re-
eptor proteins in the endomyocardial biopsy samples.
igure 5 shows the different degrees of staining for IGF-1
nd IGF-1 receptor proteins in the endomyocardial biopsy
amples obtained from 3 patients. In the left panels, brown
igure 3. Pericardial total insulin-like growth factor-1 (IGF-1) levels (A), p
atriuretic peptide (BNP) levels (D) in patient groups with New York He
ith class I. **p  0.001 compared with classes I and II.ositive immunostaining signals for IGF-1 and IGF-1 aeceptor proteins were distinct in both cardiomyocytes and
nterstitial cells and were assessed as 3. In the center
anels, the degrees of positive staining for IGF-1 and
GF-1 receptor proteins were assessed as 2, whereas in the
ight panels, the degrees were assessed as 1. Table 2 shows
he clinical profiles and the degrees of immunostaining in 4
atients with left ventricular dysfunction (cases 1 to 4) and
patients with normal left ventricular function (cases 5 to
). In all patients, some degrees of positive staining for
GF-1 and IGF-1 receptor proteins were observed. In the
atients with normal left ventricular function, the degrees of
taining for IGF-1 protein were all 1, whereas those for
GF-1 receptor protein were 1 in 2 patients and 2 in the
ther 2 patients. In the patients with left ventricular dysfunc-
ion, the degrees were all increased as 2. The degrees of
taining for IGF-1 and IGF-1 receptor proteins in the group
ith left ventricular dysfunction were higher than those in the
roup with normal left ventricular function (IGF-1: p 
.05, IGF-1 receptor: p  0.06 by chi-square test).
In one patient with dilated cardiomyopathy who previ-
usly underwent trans-sphenoidal surgery, the plasma total
GF-1 level was 14 ng/ml, whereas the pericardial total
GF-1 level was 72 ng/ml. The degrees of positive staining
or IGF-1 and IGF-1 receptor proteins were both assessed
dial free IGF-1 levels (B), plasma total IGF-1 levels (C), and plasma brain
ssociation (NYHA) functional classes I, II, and III. *p  0.05 comparedericars 2 (center panel in Fig. 5).
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IGF-1 and Heart Failure October 3, 2006:1387–95ISCUSSION
he major findings of the present study are as follows: the
ericardial total and free IGF-1 levels were increased in
atients with left ventricular dysfunction and advanced heart
ailure, and were positively correlated with the plasma BNP
evel. In contrast, the plasma total IGF-1 level was inversely
orrelated with the plasma BNP level. Furthermore, the
xpressions of IGF-1 and IGF-1 receptor protein were
nhanced in patients with decreased left ventricular function
igure 4. (A) Relationship between the plasma brain natriuretic peptide
BNP) and pericardial total insulin-like growth factor-1 (IGF-1) levels. (B)
elationship between the plasma BNP and pericardial free IGF-1 levels.
C) Relationship between the plasma BNP and plasma total IGF-1 levels.ompared with patients with normal left ventricular func- pion. These results indicate that the local cardiac IGF-1 system
s up-regulated with progression of left ventricular dysfunction,
ut is regulated differently from the circulating IGF-1 system,
hich is rather attenuated in advanced heart failure.
irculating and local IGF-1 systems in cardiovascular
isease. To estimate the cardiac IGF-1 system, we mea-
ured the pericardial IGF-1 level because many studies have
hown that pericardial fluid is useful for investigating the
everity of ischemic or failing hearts in humans (13,14).
rain natriuretic peptide is mainly produced by the failing
eart, and is released into the systemic circulation or
ericardial fluid. Moreover, both the plasma and the peri-
ardial BNP levels were increased with the severity of the
YHA functional class, and the pericardial BNP level was
-fold higher than the plasma level. These results are
onsistent with those of a previous study (15), and indicate
hat the pericardial fluid strongly reflects the circumstances
n the myocardial tissue.
Recently, IGF-1 was suggested to be locally produced in
arious tissues, such as the heart, skeletal muscle, and bone,
nd this local IGF-1 seems to play significant roles in tissue
evelopment (1,6,7). Sjögren et al. (5) showed that circu-
ating liver-derived IGF-1 is not required for postnatal body
rowth in mice, and that locally produced IGF-1 acting in
n autocrine/paracrine fashion is more important than
iver-derived IGF-1. Neri Serneri et al. (9) confirmed the
xistence of a tissue IGF-1 system in the human heart by
howing a difference in the plasma concentrations between
he aorta and coronary sinus, and by reverse transcriptase-
olymerase chain reaction and in situ hybridization analyses
n ventricular biopsy samples from patients with valvular
eart disease. To the best of our knowledge, the present
tudy is the first report to compare the pericardial (local) and
lasma (systemic) levels of IGF-1 in patients with CAD and
o suggest a role for the cardiac IGF-1 system in the
athophysiology of heart failure.
It should be pointed out that the pericardial total IGF-1
evel was lower than the plasma level. The pericardial space
s a large lymphatic sac, and the composition of the
ericardial fluid is influenced by the myocardial interstitial
uid (16). Laham et al. (17) reported that intrapericardial
elivery provides markedly higher myocardial deposition
nd retention than intracoronary or intravenous delivery. In
he present study, we measured not only the pericardial total
GF-1 level, but also the free IGF-1 level, because free
GF-1 separated from the IGF-1–IGFBP complex is bio-
ctive. The free IGF-1 level accounted for 4.2% of the total
GF-1 level in the pericardial fluid, whereas it is generally
1% of the total IGF-1 level in the plasma in healthy
ubjects (18–20). These findings suggest that even a lower
evel of pericardial IGF-1, such as that in the present study,
ay function against the failing heart.
ncreased pericardial total and free IGF-1 levels in left
entricular dysfunction. Both the pericardial total and free
GF-1 levels were inversely correlated with the LVEF in the
resent study. Ideally, we would have preferred to obtain
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October 3, 2006:1387–95 IGF-1 and Heart Failureyocardial tissue biopsy samples during CABG. However,
e were unable to do it from an ethical point of view.
lternatively, we examined the expressions of IGF-1 and
GF-1 receptor proteins immunohistochemically in the
ndomyocardial biopsy samples obtained from other pa-
ients with normal (4 patients) or impaired (4 patients) left
entricular function. This immunohistochemical results
howed that IGF-1 and IGF-1 receptor proteins were
resent in the myocardial tissue, and their expressions were
nhanced in patients with decreased left ventricular function
ompared with those in patients with normal left ventricular
unction. These findings strongly suggest that a high peri-
ardial IGF-1 level is closely related to left ventricular
ysfunction. Cardiac IGF-1 formation was previously found
igure 5. Different degrees of immunostaining for insulin-like growth fac
btained from 3 patients. 3  markedly enhanced staining; 2  mod
able 2. Degrees of IGF-1 and IGF-1 Receptor Staining in the
yocardial Biopsy Tissues Obtained From Patients With
mpaired and Normal Left Ventricular Function
Age Gender Diagnosis
LVEF
(%) IGF-1
IGF-1
Receptor
ase 1 54 M DCM 35 3 3
ase 2 71 M DCM 31 2 3
ase 3 71 F DCM 36 2 3
ase 4 34 M DCM 26 2 2
ase 5 34 F VT 53 1 2
ase 6 73 M ECG abnormality 71 1 2
ase 7 15 F ECG abnormality 68 1 1
ase 8 71 F VT 57 1 1
  mildly stained; 2  moderately stained; 3  strongly stained.
DCM  dilated cardiomyopathy; ECG  electrocardiogram; IGF-1  insulin-p
ike growth factor-1; LVEF  left ventricular ejection fraction; VT  ventricular
achycardia.o be increased in patients with increased left ventricular
all stress and athletes with physiological hypertrophy
9,21). Moreover, the myocardial IGF-1 level is increased in
n experimental myocardial infarction model (22,23). Fur-
hermore, IGF-1 mRNA expression is increased by graded
echanical stress in the rat heart Langendorff model, which
s not affected by circulating IGF-1 (24). These studies
upport the presence of a local tissue IGF-1 system in the
eart. However, it remains unclear whether left ventricular
ysfunction leads to an increased level of pericardial IGF-1
r vice versa, although many studies have reported that
GF-1 has a protective effect on the heart (2–4,25–27).
urther studies are needed.
ecreased plasma IGF-1 level in heart failure. The
lasma BNP level is well known to reflect the severity of
eart failure (28). In the present study, the plasma total
GF-1 level was inversely correlated with the plasma BNP
evel, whereas the pericardial total and free IGF-1 levels
ere positively correlated with it. Moreover, the pericardial
NP level was positively correlated with the plasma BNP
evel. Thus, the IGF-1 level shows a disparity between the
lasma and pericardial fluid. The mechanism of the decrease
n the plasma IGF-1 level still remains unclear. The plasma
otal IGF-1 level is known to gradually increase after birth,
nd then gradually decrease with age in adults. In fact, our
esults showed that the plasma total IGF-1 level was
nversely correlated with age. Previous clinical studies have
hown that the plasma total IGF-1 level is decreased in
atients with advanced heart failure (29,30) and that the
(IGF-1) and IGF-1 receptor proteins in endomyocardial biopsy samples
staining; 1  weak staining. See text for discussion.lasma IGF-1 level is inversely related to the risk of
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IGF-1 and Heart Failure October 3, 2006:1387–95ongestive heart failure in elderly people without previous
yocardial infarction (31). In the present study, the plasma
otal IGF-1 level was positively correlated with the serum
holinesterase level, which reflects the ability of protein
ynthesis in the liver. We believe that the decrease in the
lasma total IGF-1 level in patients with advanced heart
ailure results from the decreased protein synthetic activity
aused by congestive liver dysfunction. In fact, impaired
epatic function attributable to biventricular cardiac failure
nd hepatic stasis was reported to cause reduced synthesis
nd release of IGF-1 (32). It should be stressed that the
lasma BNP level was confirmed to predict LVEF and
YHA functional class, and was generally a stronger
redictor than pericardial IGF-1 (Figs. 2 and 3).
tudy limitations. Although the composition of the peri-
ardial fluid was reported to be influenced by the myocardial
nterstitial fluid (16), we do not have any direct evidence of
correlation between the IGF-1 levels in the pericardial and
nterstitial fluids. The enhanced expressions of IGF-1 and
GF-1 receptor proteins in endomyocardial biopsy samples
btained from the failing heart may explain the increased
evel of IGF-1 in the pericardial fluid. The present study
nly included patients who underwent CABG under gen-
ral anesthesia. No data were obtained from subjects with a
ormal heart because it is ethically impossible to sample
ericardial fluid from normal subjects. Therefore, it is
ifficult to compare the levels of substances in the pericardial
uid between patients with CAD and healthy subjects. We
lso were unable to obtain permission for biopsy samples
rom the ethics committee of our institute. Therefore, we
xamined the expressions of IGF-1 and IGF-1 receptor
roteins immunohistochemically in endomyocardial biopsy
amples obtained from other patients with normal or im-
aired left ventricular function.
In conclusion, the pericardial total and free IGF-1 levels
ere both increased in patients with left ventricular dys-
unction and advanced heart failure. In contrast, the plasma
otal IGF-1 level was inversely correlated with the plasma
NP level. These results indicate that the local cardiac
GF-1 system is up-regulated with progression of left
entricular dysfunction and heart failure.
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